China’s I-Mab biopharma gets USFDA’s approval for IND application for TJM2

A China-based clinical stage biopharmaceutical immuno-oncology and autoimmune diseases focused company, I-Mab Biopharma (I-Mab), said Monday it got the US Food and Drug Administration (FDA) has approval for its IND application for TJM2, a potential treatment for autoimmune and inflammatory diseases.

Read more

GenomOncology names CEO

GenomOncology, a technology solution provider for oncology, named Brad Wertz as the new Chairman and Chief Executive Officer (CEO), who’ll assume the position from the start of year 2019.  Wertz has been a founding investor and chairman of the board since the beginning, and has increased his involvement as the company has grown over the past two years. 

Read more